Volume | 468,542 |
|
|||||
News | - | ||||||
Day High | 21.51 | Low High |
|||||
Day Low | 21.43 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Fusion Pharmaceuticals Inc | FUSN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
21.50 | 21.43 | 21.51 | 21.45 | 21.49 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,879 | 468,542 | $ 21.45 | $ 10,048,432 | - | 2.31 - 21.58 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:34:53 | 1 | $ 21.4398 | USD |
Fusion Pharmaceuticals (FUSN) Options Flow Summary
Fusion Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.48B | 68.99M | - | 2.07M | -94.9M | -1.38 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Fusion Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FUSN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.40 | 21.58 | 21.37 | 21.43 | 470,476 | 0.04 | 0.19% |
1 Month | 21.32 | 21.58 | 20.97 | 21.35 | 967,534 | 0.12 | 0.56% |
3 Months | 11.28 | 21.58 | 9.09 | 18.91 | 2,146,054 | 10.16 | 90.07% |
6 Months | 4.59 | 21.58 | 3.78 | 15.49 | 1,500,787 | 16.85 | 367.10% |
1 Year | 3.83 | 21.58 | 2.31 | 14.77 | 787,907 | 17.61 | 459.79% |
3 Years | 8.65 | 21.58 | 1.98 | 12.83 | 324,816 | 12.79 | 147.86% |
5 Years | 18.50 | 21.58 | 1.98 | 12.93 | 272,507 | 2.94 | 15.89% |
Fusion Pharmaceuticals Description
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. |